Multiple sclerosis (MS) is an autoimmune disease of the central nervous system that causes an autoimmune response in the CNS through infection and environmental factors, and there is still a lack of effective treatments. Creative BioMart can provide immunotherapy services to develop specific suppression of the immune response to autoantigens to achieve effective treatment of MS by effectively reducing auto-reactive T cell responses through pMHC-coated NPs.

pMHC-NPs for MS Treatment

Unlike autoimmune experiments in which we typically use a particular antigen to actively immunologically induce disease, human MS involves complex antigens in which cells of the adaptive immune system, such as B cells and T cells, act in concert with cells of the innate immune system to cause disease. Therefore, therapeutic development solutions for MS need to consider strategies that comprehensively inhibit auto-reactive T and B cell activation in a disease-specific manner and do not compromise normal immune responses. pMHC-NPs are based on this assumption and have the ability to treat in a disease-specific manner.

MS Therapy Solutions Based on pMHC-NP

We provide solutions for a variety of pMHC- NP-based approaches for the treatment of MS, including designing structures, exploring function, and validating therapeutic relevance. Our services help guide the development of pMHC- NP therapies for MS in a better direction.

• Design nanoparticles coated with pMHC complexes. Known antigenic targets in MS development or the discovery of relevant new antigens can be exploited.
• Synthetic pMHC-NPs. Include unencapsulated nanoparticles, pMHC monomers, peptides, pMHC complexes and final synthesis products.
• MS animal model experiments. Provide studies on the effectiveness of pMHC-NP-based therapies in treating animal models of EAE.

Problems Solved

• pMHC specificity and the structural complexity and manufacturing challenges of pMHC-NPs.
• Minimize the potential immunogenicity and toxicity of synthetic NPs.
• Systematic evaluation to determine the role of pMHC-NPs in the treatment of MS.

The development of innovative MS therapies is one of the core research areas at present, and in this regard, pMHC-based nanomedicines can improve the effectiveness of conventional therapies for immune system diseases such as MS. Creative BioMart offers development services for pMHC-related drugs for autoimmune diseases, helping to fast-track our clients' projects, so that their products are expected to become powerful drugs in the MS therapeutic arsenal.

If you have ideas for pMHC-NPs therapeutics, please contact us to be your reliable partner for planning and execution.

Reference

• Yu C S, et al. "Bioconjugate Strategies for the Induction of Antigen-Specific Tolerance in Autoimmune Diseases." Bioconjugate Chemistry (2018),29(3):719-732.